Mycobacterium avium complex disease is the third most commonopportunistic disease affecting patients with AIDS. In a nationwidesurvey, it occurred in 22 percent of such patients1; only Pneumocystiscarinii pneumonia and Kaposi's sarcoma were more frequent, occurringin 58 percent and 28 percent of patients, respectively. M. aviumdisease is associated with debilitating symptoms and shortenedsurvival.2 Thus, the reports in this issue of the Journal thatdocument improved regimens for the prevention3,4 and treatment5of this disease are welcome news.
Clarithromycin and azithromycin both have good in vitro activityagainst M. avium, and it is not . . . [Full Text of this Article]
Field, S. K., Fisher, D., Cowie, R. L.
(2004). Mycobacterium avium complex Pulmonary Disease in Patients Without HIV Infection. Chest
126: 566-581
[Abstract][Full Text]
Grouhi, M., Wang, E., Reid, B., Roifman, C. M.
(1999). Long-term Remission for Disseminated Mycobacterium avium-intracellulare Complex Associated With Antibody Deficiency. Pediatrics
103: e13-13
[Abstract][Full Text]
Phillips, A. N., Smith, G. D., Feder, H. M., Milch, L. R., Srinivasan, V., Beidas, S. O., Corey, L., Holmes, K. K., Katzenstein, D., The AIDS Clinical Trials Group, , Study 175 Investigators,
(1997). Viral Load and Combination Therapy for Human Immunodeficiency Virus. NEJM
336: 958-961
[Full Text]
(1996). PREVENTING AND TREATING DISSEMINATED MAC IN AIDS. JWatch General
1996: 4-4
[Full Text]